Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trialsMassimo Gentile, Pellegrino Musto, Silvia Mangiacavalli et al.|Haematologica|2023Cited by 19
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trialsEnrica Antonia Martino, Pellegrino Musto, Salvatore Palmieri et al.|Hematological Oncology|2024Cited by 7
Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by “rete ematologica pugliese”Giuseppe Mele, Domenico Pastore, Nicola Di Renzo et al.|Leukemia & lymphoma/Leukemia and lymphoma|2023Cited by 2
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID StudyNicola Sgherza, Pellegrino Musto, Olga Battisti et al.|Pharmaceuticals|2025Cited by 2
Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica PuglieseNicola Di Renzo, Pellegrino Musto, Emanuela Resta et al.|Annals of Hematology|2025Cited by 0